MedPath

The Role of HMGB-1 in Chronic Stroke

Terminated
Conditions
Cerebral Stroke
Stroke, Acute
Cerebrovascular Accident
Registration Number
NCT01705353
Lead Sponsor
Northwell Health
Brief Summary

The purpose of this study is to measure the presence of HMGB-1 and other proteins in the blood across five time points after stroke, and to determine if their presence correlates with rate of stroke recovery.

Detailed Description

Stroke, cerebrovascular accident, is the leading cause of brain injury and the leading cause of permanent disability. The acute pathophysiology of stroke depends on the innate immune response, which arises from mostly pro-inflammatory cascades. The chronic pathophysiology of stroke is less clear as the innate inflammatory response fades and matures into an adaptive immune response. HMGB-1 is a serum cytokine that has been found with persistent elevated levels for weeks to months after neurological insult in preclinical experiments, and may retard functional recovery. Elucidation of the relationship between HMGB-1 levels and the rate of functional recovery after stroke could lead to a better understanding of the systemic inflammatory response and more targeted therapeutic interventions.

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
39
Inclusion Criteria
  • Patients admitted to the stroke service at Northshore and LIJ Medical Centers
  • Patients 18 years of age or older
Exclusion Criteria
  • Patients < 18 years of age

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Cytokine levels (HMGB-1) in plasma samplesday 1, day7, day 14, day 30, day 90
Secondary Outcome Measures
NameTimeMethod
NIH and Rankin Clinical Measures of functional recoveryday 1, day7, day 14, day 30, day 90

Trial Locations

Locations (2)

Long Island Jewish Medical Center

🇺🇸

New Hyde Park, New York, United States

North Shore University Hospital

🇺🇸

Manhasset, New York, United States

© Copyright 2025. All Rights Reserved by MedPath